Acute graft-versus-host disease (GVHD), a reaction of donor immune cells against host tissues, is a frequent complication (35%-50%) after allogeneic hematopoietic stem cell transplantation (HSCT).
pigment was seen in the corneum. Focal mild epidermal clefting was seen. Superficial debris showed minimal perivascular lymphocytic infiltrate. Dermis showed loss of pilosebaceous structures and thickened collagen bundles in the papillary and reticular dermis [ Figures 1-4 ].
Bone marrow aspiration smears were particulate and showed markedly hypocellular particles. Erythroid and myeloid precursors were markedly reduced in number and only scattered forms were seen exhibiting normal morphology. Megakaryocytes appeared to be adequate. Background population of lymphocytes and macrophages was seen [ Figures 5 and 6 ].
Chimerism study on the bone marrow specimen showed that 49% cells show XX pattern (female donor) and 51% cells show XY pattern (patient).
Based on the clinical picture, histology, and bone marrow findings, a diagnosis of acute GVHD with dermal sclerodermoid features was made. The patient was treated with methylprednisolone and intravenous basiliximab. Immunosuppression was continued. Despite aggressive treatment, the patient continued to deteriorate and died within a week of presentation due to multiorgan failure. discussiOn GVHD in OLT is rare but has a mortality rate of 85%. [1, 4, 7] In OLT, immunocompetent donor-derived lymphocytes undergo activation following exposure to recipient-derived antigens. Activated donor T-lymphocytes mediate an immune response against recipient tissue. [7] The target tissues in GVHD following OLT are the bone marrow, skin, and the gut, with notable sparing of the liver. [7] The pathogenesis of GVHD in OLT occurs in three continuous phases. In the first phase, surgery induces a pro-inflammatory state where host macrophages release tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1), resulting in increased host antigen-presenting cell activity. In the second phase, donor-derived T-lymphocytes residing in the donor's liver activate, stimulated by the HLA/peptide complex interactions, resulting in IL-2 receptor expression and clonal expansion, ultimately leading to the release of pro-inflammatory cytokines IL-2 and interferon gamma. [3, 7] In the third phase, anti-host T-cells release granzyme and perforin, leading to further inflammation and promotion of GVHD. [7, 8] In OLT, GVHD presents 1-8 weeks after transplant. [1, 7] In 15% of cases, the patient presents with only dermatologic symptoms of rash involving the palms and soles, with eventual bullous transformation and desquamation. [6, 7] GVHD resulting in multisystem organ failure has an 85% mortality rate. The natural history of post-OLT GVHD is a relapsing-remitting pattern of diarrhea, rash, fever, and neutropenia, culminating in sepsis and death. [7] A diagnosis of GVHD after OLT is confirmed by biopsy of the affected tissues, which will demonstrate donor-derived lymphocytic infiltration in the appropriate clinicopathological setting. [5, 7] GVHD should be suspected in symptomatic patients if chimerism is demonstrated by polymerase chain reaction or HLA typing of lymphocytes in the peripheral blood. [1, 5, 6] Early recognition requires thoughtful synthesis of the pathological, laboratory, and clinical data, and prompt treatment is essential. [5] There are no guidelines for the treatment of post-OLT GVHD. Current therapy is borrowed from GVHD treatment following HSCT and consists of immunosuppression with high doses of corticosteroids or calcineurin inhibitors. [5, 7, 8] However, this is frequently complicated by toxicity and infections. [5] [6] [7] [8] [9] Salvage therapies in steroid-refractory GVHD after OLT are mostly ineffective. Administration of OKT3 or anti-thymocyte globulin (ATG) produces a profound immunosuppression but is not associated with remission and frequently results in fatal infections. [5, 7] Targeting T-lymphocytes with daclizumab and basiliximab are associated with remission of skin GVHD but are usually inadequate in suppressing gut GVHD. [5, 7] Anti-TNFα agents are also not effective in treating GVHD and are associated with fungal infections. [4, 9] Decreasing immunosuppression following LT allows host lymphocytes to regain activity against donor lymphocytes with the risk of graft rejection. [4, 6, 9] Finally, T-lymphocyte elimination with ATG or irradiation has not proven to be worthwhile due to the unknown risk of impairing engraftment. [1, 7, 10] Extracorporeal photopheresis has been effective in GVHD following HSCT and is regarded as a second-line treatment, resulting in response rates as high as 80% and up to 50% long-term survival, but its role in post-LT GVHD is not clear. [9, 11, 12] 
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